-+ 0.00%
-+ 0.00%
-+ 0.00%

Learn Why The Bull Case For Oscar Health Stock Could Change Following Raised Earnings Guidance

Simply Wall St·11/16/2026 23:22:07
Listen to the news
  • Oscar Health reported third quarter 2026 revenue of US$5,139.3 million and net income of US$167.28 million, then raised full year 2026 revenue guidance to a range of US$19.0 billion to US$19.3 billion and earnings from operations guidance to a range of US$850 million to US$950 million.
  • The shift from a net loss of US$137.45 million a year earlier to profit, alongside higher guidance, signals a material change in Oscar Health’s operating profile and cost discipline.
  • The focus now is on how this stronger guidance reshapes Oscar Health’s earlier high-upside investment narrative, particularly in relation to earnings power.

Scan Oscar Health’s latest guidance shift in the context of a broader peer set by hunting for insurers and healthcare players with similar earnings momentum in the curated 37 healthcare AI stocks.

Oscar Health Investment Narrative Recap

For an investor to own Oscar Health, there needs to be confidence that the current profitability is durable and that the business can keep converting premium growth into earnings without letting medical costs run away. The raised 2026 revenue and operating earnings guidance points to management seeing enough visibility in membership and pricing to support stronger near term performance.

The key short term catalyst is continued proof that underwriting discipline holds through upcoming renewal cycles while the member base grows. The largest risk is that medical loss trends or pricing missteps erode margins, which would challenge the new guidance and reopen questions about the sustainability of Oscar Health’s earnings profile.

The HealthEx collaboration looks most relevant here because it plugs directly into Oscar Health’s thesis as a tech driven insurer. Members can choose to connect medical records from clinics, hospitals, and labs into the Oscar app from day one, which gives the insurer a more complete view of conditions, medications, and prior care pathways.

That operationally matters for both catalysts and risks. Better data may help Oscar match members to in network doctors, manage chronic conditions earlier, and reduce avoidable high cost claims, which feeds into earnings quality. At the same time, the integration increases reliance on secure data handling and consistent execution in the app, so any issues around privacy, uptime, or user experience could dent trust and reduce the practical benefit of the partnership.

J_Tyrader’s narrative reaches a fair value of US$583.34 for Oscar Health by applying a two stage DCF that assumes 25.0% annual growth for 10 years, fading to a 2.5% terminal rate and discounting those cash flows at 9.6%.

Uncover how Oscar Health's fair value indicates a 1762% potential increase from its current price that may not last much longer.

NYSE:OSCR 1-Year Stock Price Chart
NYSE:OSCR 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the highest ranked analysts were already leaning into Oscar Health’s tech stack as a catalyst, expecting revenue of about US$30.4b and earnings near US$1.3b by 2029, compared with around US$550.7m of earnings in their starting point. Those projections did not factor in this HealthEx rollout, so you may see those stories evolve.

Explore 5 other Oscar Health fair value estimates, including one that suggests up to 1762% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking for more investment ideas beyond Oscar Health?

Once you have formed a view on Oscar Health, it can help to line it up against a wider opportunity set so you can decide where it fits in your portfolio.

  • For investors hunting for strong businesses that already look attractively priced on key fundamentals, start with a focused set of 37 high quality undervalued stocks that may merit a closer look.
  • If capital preservation and balance sheet resilience matter most to you, filter for companies with robust finances using a curated list of solid balance sheet and fundamentals (24 results) to compare against your current holdings.
  • When you want potential mispriced opportunities that are not widely followed, broaden your watchlist with a hand picked pool of 19 high quality undiscovered gems that combine quality indicators with thinner coverage.